Journal of Pigmentary Disorders

The document discussed advancements in acne treatment, highlighting clascoterone and minocycline. Clascoterone, an androgen receptor antagonist, reduced lesions in 2 trials with 1440 participants by decreasing sebum production and inflammation. Minocycline, approved by the FDA in 2019, showed efficacy in a study with 1488 patients, achieving treatment success in 30.8% of cases. It was noted for its quick efficacy and favorable adverse effects profile compared to other tetracyclines. Sarecycline was also recommended for its narrow-spectrum antibiotic properties, aiming to reduce resistance.